Document Detail


Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
MedLine Citation:
PMID:  16287955     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Coronary artery bypass graft (CABG) surgery with autologous vein grafting is commonly performed. Progressive neointimal hyperplasia, however, contributes to considerable vein graft failure. Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure.
OBJECTIVE: To assess the efficacy and safety of pretreating vein grafts with edifoligide for patients undergoing CABG surgery.
DESIGN, SETTING, AND PARTICIPANTS: A phase 3 randomized, double-blind, placebo-controlled trial of 3014 patients undergoing primary CABG surgery with at least 2 planned saphenous vein grafts and without concomitant valve surgery, who were enrolled between August 2002 and October 2003 at 107 US sites.
INTERVENTION: Vein grafts were treated ex vivo with either edifoligide or placebo in a pressure-mediated delivery system. The first 2400 patients enrolled were scheduled for 12- to 18-month follow-up angiography.
MAIN OUTCOME MEASURES: The primary efficacy end point was angiographic vein graft failure (> or =75% vein graft stenosis) occurring 12 to 18 months after CABG surgery. Other end points included other angiographic variables, adverse events through 30 days, and major adverse cardiac events.
RESULTS: A total of 1920 patients (80%) either died (n = 91) or underwent follow-up angiography (n = 1829). Edifoligide had no effect on the primary end point of per patient vein graft failure (436 [45.2%] of 965 patients in the edifoligide group vs 442 [46.3%] of 955 patients in the placebo group; odds ratio, 0.96 [95% confidence interval {CI}, 0.80-1.14]; P = .66), on any secondary angiographic end point, or on the incidence of major adverse cardiac events at 1 year (101 [6.7%] of 1508 patients in the edifoligide group vs 121 [8.1%] of 1506 patients in the placebo group; hazard ratio, 0.83 [95% CI, 0.64-1.08]; P = .16).
CONCLUSIONS: Failure of at least 1 vein graft is quite common within 12 to 18 months after CABG surgery. Edifoligide is no more effective than placebo in preventing these events. Longer-term follow-up and additional research are needed to determine whether edifoligide has delayed beneficial effects, to understand the mechanisms and clinical consequences of vein graft failure, and to improve the durability of CABG surgery. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00042081.
Authors:
John H Alexander; Gail Hafley; Robert A Harrington; Eric D Peterson; T Bruce Ferguson; Todd J Lorenz; Abhinav Goyal; Michael Gibson; Michael J Mack; Daniel Gennevois; Robert M Califf; Nicholas T Kouchoukos;
Related Documents :
23073305 - Dual antiplatelet agent-induced spontaneous liver hematoma (november).
21054805 - Five-year follow-up of peyronie's graft surgery: outcomes and patient satisfaction.
24074945 - Spontaneous methicillin-sensitive staphylococcus aureus spondylodiscitis-short course a...
306575 - Long-term anatomic fate of coronary-artery bypass grafts and functional status of patie...
337995 - Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a ...
18344885 - Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic ...
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JAMA     Volume:  294     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-18     Completed Date:  2005-11-22     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2446-54     Citation Subset:  AIM; IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00042081
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiography
Coronary Artery Bypass*
DNA / therapeutic use*
Double-Blind Method
E2F Transcription Factors
Female
Genetic Therapy* / methods
Graft Occlusion, Vascular / prevention & control*
Humans
Hyperplasia
Male
Middle Aged
Oligonucleotides / therapeutic use*
Saphenous Vein / drug effects*,  pathology,  radiography,  transplantation*
Survival Analysis
Tissue and Organ Harvesting
Transfection
Transplantation, Autologous
Transplants*
Vascular Patency / drug effects*
Chemical
Reg. No./Substance:
0/E2F Transcription Factors; 0/Oligonucleotides; 0/edifoligide; 9007-49-2/DNA
Comments/Corrections
Comment In:
JAMA. 2006 Apr 5;295(13):1513-4; author reply 1514-5   [PMID:  16595750 ]
JAMA. 2006 Apr 5;295(13):1513; author reply 1514-5   [PMID:  16595751 ]
JAMA. 2005 Nov 16;294(19):2495-7   [PMID:  16287962 ]
JAMA. 2006 Apr 5;295(13):1514; author reply 1514-5   [PMID:  16595752 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarctio...
Next Document:  Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids:...